Air purifier developer 352Air has closed a $30-million Series A round, while precision medicine startup AnchorDx Corp has raised $28 million in a Series B round, the China Money Network reported.
352Air raises $30m Series A
Other investors that joined the round include Matrix Partners China, Huatai New Industry Growth Investment Fund and Atlas Capital.
352Air makes household air purifiers, automotive air conditioning filters, car purifiers, air quality detectors and anti-haze masks.
China has been battling rising air pollution for years now. Cities like Beijing, Shanghai, Guangzhou and Xi’an are witnessing PM2.5 concentration levels, which exceed the World Health Organization’s air quality guidelines.
AnchorDx raises $28-million Series B
AnchorDx Corp, which specializes in the development of new clinical diagnosis products using high-throughput gene sequencing technology, has raised a $28-million Series B round co-led by 6 Dimensions Capital and Sijia Jianxin Fund.
The round was joined by ARCH Venture Partners, Marathon Venture Partners, KingMed Diagnostics and WuXi AppTec Group.
Founded in 2015, AnchorDx focuses on applying high-throughput sequencing of methylated circulating tumour DNA (ctDNA) to diagnose early-stage cancer.
It has previously raised undisclosed funding from Marathon Venture Partners and Northern Light Venture Capital, the China Money Network report said.